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Background. Current evidence indicates that statins increase the risk of new onset diabetes mellitus (NOD) and also deteriorate the
glycemic control in patients with known diabetes mellitus (DM) after high-dose statin therapy. Aims. The aim of this review was to
explore the eﬀect of atorvastatin in causing NOD or deteriorating glycemic control in patients with DM.Methods. Two independent
reviewers conducted the literature search, through PubMed database searching for articles published in English until April 2015,
and only primary studies were included. Results. Of the 919 articles identiﬁed in our original search, 33 met the criteria for this
review encompassing 1,951,113 participants. Twenty articles examined dysregulation of DM due to atorvastatin. Half of them
showed that there was no signiﬁcant change in glycemic control in patients treated with atorvastatin. Other studies showed that
fasting plasma glucose and HbA1c levels were increased by atorvastatin. Thirteen articles examined if atorvastatin causes NOD.
The majority of these articles showed that patients who used atorvastatin had a higher dose-dependent risk of developing NOD.
Conclusion. This systematic review suggests that there is an association between atorvastatin treatment and NOD. Moreover, it
showed that atorvastatin in high dose causes worsening of the glycemic control in patients with DM.
1. Introduction
Dyslipidemia is a primary well-established independent risk
factor for cardiovascular disease [1]. An eﬀective treatment,
the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors (also known as statins) are proven to
lower low-density lipoprotein (LDL) cholesterol levels in
patients with hypercholesterolemia [2].
Multiple prospective studies have showed the cardio-
protective and antioxidant eﬀects of statins, which have
widely and for many decades been used for that purpose
[3, 4]. LDL-cholesterol levels remain the principal target
for lipid modiﬁcation and statin therapy as the main treat-
ment of achieving LDL goal attainment. The beneﬁcial
eﬀect of statins in both primary and secondary prevention
of cardiovascular events by lowering LDL-cholesterol con-
centrations has been documented among patients with or
without diabetes [5, 6].
Diabetes mellitus is a growing public health problem that
is approaching epidemic proportions globally, and it is also
related with increased cardiovascular risk. In adults aged
over 40 with diabetes mellitus, according to the American
Diabetes Association (ADA) [7] and ACC/AHA guidelines
[8], statin treatment is recommended, while it should also
be considered for those less than 40 years old based on
their risk proﬁle.
Statin therapy is associated with signiﬁcant reduction in
cardiovascular endpoints; however, concerns have been
raised over the use of statins and an increased risk of diabetes.
Several statins are now available, with diﬀerent potencies
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and drug interactions such as atorvastatin, pitavastatin, sim-
vastatin, and rosuvastatin. However, their inﬂuence on insu-
lin levels and insulin resistance has not been clariﬁed yet.
There are some theories suggesting a potential risk of devel-
oping new onset diabetes mellitus (NOD) [9] or a risk of
deteriorating the glycemic control in patients with diabetes
after high-dose statin therapy [10]. This risk is seemingly
elevated with the use of atorvastatin [11]. Therefore, many
clinical trials [12–14] have investigated the possible associa-
tion between atorvastatin and new onset diabetes or dysreg-
ulation of already existing diabetes as well as the underlying
mechanisms. It has also been reported that some groups with
special characteristics, such as postmenopausal women [15]
and renal allograft recipients [16], are in particular danger.
On the other hand, few studies have demonstrated that ator-
vastatin did not worsen insulin sensitivity in patients with
diabetes [17, 18], whereas one study suggested that patients
treated with atorvastatin may be at a lower risk of developing
new onset diabetes [14].
The aim of this review was to look systematically into the
current literature and carefully collect and analyse results to
explore the potential eﬀect of atorvastatin in both causing
new onset diabetes and deterioration of glycemic control in
patients with known diabetes.
2. Methods
2.1. Literature Search. This review has adopted the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines. A systematic search strategy was
followed. PubMed database was used to search for publica-
tions of interest using as keywords “atorvastatin AND dia-
betes.” Eligible studies were primary studies of every design
(observational studies, cross-sectional, cohort, case studies,
case series, clinical trials, etc.) published in English until 30/
04/2015 (date of last search). Secondary studies (reviews,
letters, and meta-analyses) as well as studies published in
languages other than English were excluded. Two reviewers
working independently conducted the literature search.
2.2. Data Collection and Synthesis. The titles of studies, which
were considered for retrieval, were recorded on a form and
then were classiﬁed on an inclusion and exclusion search
diary. All the articles that came up but were irrelevant or were
secondary research were excluded. Studies were selected for
retrieval after two independent reviewers had collected titles
and abstracts identiﬁed in electronic searches. The results of
the two reviewers were compared by a third independent
reviewer, and any diﬀerences of opinion were resolved by
discussion. The corresponding authors were contacted on
account of missing data. The included studies were grouped
and presented in Summary Tables featuring key points of
each study; the following data were collected: ﬁrst author
surname, study name, year of publication, study design,
country, number of total population (percentage of male/
female), total population age (Mean-Standard Deviation-
Median range), Quantitative results (HR, p) of the study
ﬁndings, diabetes status of the participants, and evidence
of association between atorvastatin use and new onset
diabetes mellitus or increased risk for worsening of glyce-
mic control. Outcome measures of included studies were
organized and then analysed cumulatively. Given the lack
of primary data, a narrative form of synthesis was adopted
as a way of expressing and synthesizing the results of the
eligible studies (i.e., numerical data expressed as weighted
means whenever possible). No further statistical analysis
was possible.
3. Results
In total, 919 articles were identiﬁed through database
searching, which were reduced to 642 articles after removing
duplicates. In all, 33 articles were eligible for the review,
following exclusions. Eighteen clinical trials [1–3, 5, 9, 10,
13, 17, 19–28], 14 cohort studies [11, 12, 14–16, 18, 29–36],
and one case control study [37] involving a total of
1,951,113 participants were included in the current review.
A relevant ﬂow chart was constructed to detail the number
of papers retrieved and the steps undertaken (Figure 1).
It should be noted that the primary endpoints of
the included studies were cardiovascular disease, LDL-
cholesterol levels, HDL-cholesterol levels, or other outcomes
such as serum triglyceride levels, apolipoprotein B, serum
dehydroepiandrosterone sulfate levels, and C-reactive
protein levels. However, all the included studies reported
evidence of glycemic control or the incidence of new onset
diabetes as secondary endpoints. The proportion of
females in the studies ranged between 0% and 100%. More
speciﬁcally, the total female population was 1,197,855–
1,197,955 (approximately 1,197,900) (61.4%). Three studies
had only females [15, 25, 37] and 2 studies had only males
[28, 34]. In the majority of studies, females were almost as
many as males.
The mean average age of the subjects by study (for which
age data were available) ranged between 44 and 74.9 years.
Thirteen studies included only patients with type 2 diabetes
mellitus [2, 3, 10, 11, 17–19, 21, 27–30, 33], while 3 stud-
ies included only patients with type 1 diabetes mellitus
[13, 20, 24]. The average time since diagnosis of diabetes
ranged between 4 and 26 years. The participants had been
followed for an average of 4 months to 5 years (weighted
average, 3.6 years).
Of note, Koh et al. [9] compared the eﬀect of atorvastatin
at doses of 10mg, 20mg, 40mg, and 80mg. Fasting plasma
insulin (mean changes: 25%, 42%, 31%, and 45%) and HbA1c
levels (2%, 5%, 5%, and 5%) were increased by atorvastatin
10, 20, 40, and 80mg when contrast with either baseline (all
p < 0 05 by paired t-test) or placebo (p = 0 009 for insulin
and p = 0 008 for HbA1c by ANOVA). Atorvastatin 10, 20,
40, and 80mg declined insulin sensitivity (1%, 3%, 3%, and
4%, respectively) when compared with either baseline
(p = 0 312, p = 0 008, p < 0 001, and p = 0 008, respectively,
by paired t-test) or placebo (p = 0 033 by ANOVA).
Baseline characteristics of the enrolled participants
were generally similar between the groups in each study.
Information regarding the included studies is presented in
Tables 1 and 2.
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The mean baseline HbA1c across the studies (weighted
average) was 7.2% (56mmol/mol) in the statin group and
7.3% (57mmol/mol) in the control group. At the end of
the studies, the mean HbA1c was 7.4% (57mmol/mol)
in the statin group and 7.2% (55mmol/mol) in the con-
trol group. The mean baseline fasting glucose across the
studies (weighted average) was 7.28mmol/L in the atorva-
statin group and 7.49mmol/L in the control group. At the
end of the studies, the mean fasting glucose was
7.84mmol/L in the atorvastatin group and 7.20mmol/L
in the control group.
3.1. New Onset Diabetes Mellitus. Thirteen articles [1, 12, 14–
16, 22, 26, 31, 32, 34–37], 3 of which were clinical trials,
examined the association between atorvastatin use and
NOD. Patients who used atorvastatin had a higher risk
of developing NOD. Also, the results of the majority of
studies indicated that the risk of diabetes was dose depen-
dent for atorvastatin. The majority of the articles and all
the clinical trials showed that high-dose, compared with
lower-dose, atorvastatin increased the risk of NOD. Waters
et al. [22] noted that in the TNT clinical trial the HR was
1.10 between those who took atorvastatin 10mg and
80mg. Further, the absolute rates of new onset T2DM were
6.40% in the group who took atorvastatin and 6.06% in the
placebo group according to the SPARCL clinical trial. The
SPARCL clinical trial was a multicenter, double blind,
parallel-group, randomized, placebo-controlled trial which
randomized patients with prior stroke or transient ische-
mic attack (TIA) but without known heart disease [38].
However, in one study, the low dose of atorvastatin was
related to a small increased risk of NOD (OR: 1.99, 95% CI:
1.00–3.98, p value 0.050) [36].
Moreover, statin medication use in postmenopausal
women was shown to be associated with an increased risk
for DM [15].
3.2. Dysregulation of Glycemic Control. Twenty articles
examined if deterioration of diabetes mellitus is associated
with the use of atorvastatin [2, 3, 5, 9–11, 13, 17–21, 23–
25, 27–30, 33], 15 of which were clinical trials. Worsening
of glycemic control was examined by measuring parame-
ters related to glucose level such as fasting plasma glucose
and HbA1c.
Ten studies showed that there was no signiﬁcant change
in glycemic control in patients treated with atorvastatin
[2, 3, 17–19, 24, 27–30].
On the other hand, in 8 studies, atorvastatin use tended
to be an independent predictor of increasing HbA1c levels
and/or fasting plasma glucose levels (p < 0 001) [9–11, 13,
20, 21, 23, 33].
In addition, it was noticed that fasting plasma glucose
and HbA1c increased in the group that received higher doses
of atorvastatin [5].
The rates of new onset T2DM were higher in groups
that took higher dose of atorvastatin. The absolute rates
of new onset T2DM were 9.24% in the group who took
80mg atorvastatin and 8.11% in the group who took 10mg
atorvastatin according to the TNT clinical trial [22].
Among clinical trials, the majority of studies indicated that
Articles identiﬁed through
database searching
(n = 919)
Articles aer duplicates
removed
(n = 642)
Articles excluded
(secondary research)
(n = 57)
Articles included
(n = 33)
Articles about DM
dysregulation
(n = 20)
Articles about
new onset DM
(n = 13)
Articles excluded
(irrelevant)
(n = 552)
Figure 1: Flowchart of the systematic review process.
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deregulation of diabetes mellitus (expressed mostly with
increased HbA1c levels) was more frequent in the statin
group than in the placebo group.
4. Discussion
Evidence from randomized clinical trials suggests that the
beneﬁts from preventing cardiovascular disease and mor-
tality with statins overweigh the risk of new onset diabetes
mellitus [39]. Nevertheless, in patients at low risk for
cardiovascular implications, lipid-lowering therapy with
statins should be carefully used, and lifestyle changes along
with close blood glucose levels monitoring should constitute
the ﬁrst line of treatment [40]. Therefore, it is absolutely
necessary for clinical doctors to evaluate the positive and
the potential negative eﬀects of statin therapy, taking into
consideration the unique characteristics of each patient.
However, according to several studies, the risk of
developing NOD varies with diﬀerent types of statins.
Patients who are treated with pravastatin and pitavastatin
are in lower risk for adverse eﬀects [41] than those treated
with lipophilic statins, such as atorvastatin [11]. Further-
more, the dose of atorvastatin plays an important role.
Higher dosage and more intensive treatment are associated
with greater incidence of NOD [42]. It should also be noted
that older patients, with impaired fasting glucose prior to
the use of statins and with other characteristics of the meta-
bolic syndrome, face a greater risk for diabetogenicity [43].
Not many systematic reviews or meta-analyses investi-
gating the association of atorvastatin with NOD and glyce-
mic control dysregulation have been published recently.
More speciﬁcally, the latest review [44] examining this asso-
ciation, published in 2017, referred only to the correlation
between diﬀerent statins and new onset diabetes mellitus
and did not provide detailed data concerning atorvastatin.
Also, four previous meta-analyses [45–48] and one review
[49] included data concerning all diﬀerent statins and
NOD, but there were no data about statins deteriorating
the glycemic control in patients with preexisting diabetes.
One meta-analysis [50] and one review [51] underlined
only the detrimental eﬀect of atorvastatin, among other
statins, on the glycemic control in diabetic patients, unlike
our review which is mainly concentrated on the eﬀect of
atorvastatin speciﬁcally on both NOD and deterioration
of the glycemic control.
4.1. New Onset Diabetes Mellitus. In this review, we found
that there is an association between atorvastatin use and
new onset diabetes (NOD). The diabetogenic eﬀect is more
signiﬁcant with high dose of atorvastatin [1, 32, 34, 37],
although new data from a most recent cohort study suggest
that low-dose atorvastatin (10–20mg) consists a risk factor
for NOD [36], though results were based on a relatively small
number of participants (N = 818). A recent study investi-
gated whether there is association between statin use and
new onset diabetes in postmenopausal women who took part
in the Women’s Health Initiative. It was revealed that all
statins increase the risk of type 2 diabetes mellitus. Particu-
larly, atorvastatin was associated with 61% increased risk of
diabetes [15]. One cohort study demonstrated that, in com-
parison with pravastatin, patients treated with atorvastatin
faced a 22% increase in the risk of new onset diabetes [12].
Another analysis, which collated data from 3 diﬀerent clinical
trials (TNT, SPARCL, and IDEAL) on atorvastatin, suggested
that atorvastatin at the maximum dose (80mg) increased the
risk for new onset diabetes by 34%, and this was more obvi-
ous in the SPARCL trial [22]. Later results from the same
clinical trials indicated that the risk for new onset diabetes
for patients with 2–4 risk factors was elevated by 24% with
high-dose atorvastatin, while there was no diabetogenic eﬀect
on patients with 0–1 risk factor [1]. It should also be men-
tioned that atorvastatin treatment caused dysglycemia
(impaired fasting glucose and diabetes mellitus) in a high
percentage of renal allograft recipients as indicated by a
recent cohort study [16]. However, a retrospective cohort
study has shown that atorvastatin had a neutral eﬀect on
new onset diabetes, which is dose-response [31], and another
study reported that not only does atorvastatin not elevate the
risk of diabetes but also may have a protective eﬀect for
elderly hypertensive and dyslipidaemic patients [14]. A
potential explanation for this may be that the participants
had median age of 74.9 years, and there is no record of the
dosage of atorvastatin used during the study. No association
between atorvastatin and new onset diabetes was demon-
strated by one study [26], but this may be attributed to the
fact that the lowest dose of atorvastatin (10mg) was used
for this study.
4.2. Dysregulation of Glycemic Control. As far as glycemic
control is concerned, this review has shown that high dose
of atorvastatin is associated with the deterioration and
worsening of glucose homeostasis [13, 21, 23, 33]. A clinical
trial published in 2010 reported that atorvastatin 10mg com-
pared to atorvastatin 80mg increased fasting plasma glucose
(FPG) by 25% and 45%, respectively, and HbA1c by 2% and
5%, respectively [9]. The inﬂuence of high-dose atorvastatin
on glycemic control was also demonstrated by 2 diﬀerent
studies, which reported a signiﬁcant increase (0.3%) of
HbA1c compared to baseline along with no alteration in
FPG levels [10, 20].
No signiﬁcant changes in glycemic control between
the atorvastatin group and the control group were found
by a clinical trial in China [19], but this was a low-
quality study (follow-up of 6 months in population of
80 patients and the exact dose of atorvastatin used was
not reported). Furthermore, a mediocre increase (0.06%)
of HbA1c was documented for patients treated with
atorvastatin compared to the control group according to
a recent study; however, no data regarding the dosage of
atorvastatin were available [30]. Another study that has
also shown no diﬀerence in the glycemic control is a clin-
ical trial from Greece, which included only 79 participants
who were treated with a low dose (10mg) of atorvastatin
[18]. A neutral eﬀect of atorvastatin 10mg was also reported
by 3 more studies [3, 27, 28]. Finally, 2 clinical studies
which used atorvastatin 20mg [2, 25] and one with atorva-
statin groups of 10-20-40mg, respectively [17, 25], showed
no association.
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A positive eﬀect on HbA1c levels was suggested by one
study investigating the eﬀects of atorvastatin in renal func-
tion of patients with diabetes [29]. This retrospective cohort
study showed that HbA1c was signiﬁcantly decreased at 1,
2, and 3 years. There was no information about the dosage
of atorvastatin. In a diﬀerent trial, a nonsigniﬁcant decrease
of HbA1c was reported in patients treated with atorvastatin
high dose (80mg) compared to placebo [24].
4.3. Mechanisms. Lipid-lowering drugs intervene with glu-
cose control and insulin sensitivity in many diﬀerent ways.
Mainly, HbA1c and FPG are aﬀected. Although the precise
underlying pathogenetic mechanisms that lead to the devel-
opment of diabetes are not yet scientiﬁcally proven, there
are some studies which suggest that the intervention of
statins in the Mevalonate path and hence in the isoprenoids’
synthesis is connected with the deterioration of glycemic
control [9]. Statin treatment also results in the downregula-
tion of glucose transporter 4 (GLUT4) in adipocytes, which
causes insulin resistance [52]. Furthermore, statins decrease
insulin secretion via the decrease of glucose-dependent intra-
cellular calcium concentration [53] and via the inhibition of
ubiquinone (CoQ10), which leads to reduction of ATP in
pancreatic β-cells [54]. These eﬀects are more intense with
lipophilic statins like atorvastatin than with hydrophilic
statins like pravastatin [55]. Other plausible mechanisms,
including genetic factors, have also been explored but with
no concrete evidence yet.
4.4. Drugs That May Have a Metabolic Eﬀect on Insulin
Resistance and on the Development of Diabetes. Several
classes of antidiabetic drugs are available. Each category has
a distinct pathophysiological mechanism of action and
consequently a diﬀerent eﬀect regarding insulin resistance
and β-cell pancreatic function.
Indicatively, metformin inhibits hepatic gluconeogenesis
and also improves insulin sensitivity via activation of AMP-
activated protein kinase (AMPK) signalling and reducing
cAMP (cyclic adenosine monophosphate) levels. Moreover,
metformin is associated with microbiome modiﬁcation of
the gastrointestinal tract and entails an increase of incretin
(glucagon-like peptide-1, GLP-1) secretion and glucose
utilization [56].
Pioglitazone binds and activates the peroxisome
proliferator-activated receptor (PPAR) γ leading to meta-
bolic changes concerning carbohydrate and lipid metabo-
lism. It is associated with an increase in tissue sensitivity to
insulin and subsequently an enhanced glucose uptake in the
skeletal muscle and adipose tissue. Also, it causes a reduction
in hepatic glucose production and an increase in hepatic
glucose uptake. It may stimulate β-cell insulin production
and may have beneﬁcial eﬀects both on endothelial and
pancreatic β-cells [57–59].
Sulfonylureas stimulate the endogenous secretion of
insulin from pancreatic β-cells by inhibiting the ATP-
sensitive K-channels. Therefore, sulfonylureas exert their
eﬀects only when residual β-cells exist [60, 61].
Reduced incretin levels may play a part in the pathogen-
esis of T2DM. Incretin-based therapies, dipeptidyl peptidase-
4 (DPP-4) inhibitors, and GLP-1 receptor agonists (GLP-
1RAs) aﬀect glucose control via pleiotropic mechanisms
and play a signiﬁcant role in glucose homeostasis.
GLP-1RAs enhance glucose-dependent insulin secre-
tion, delay gastric emptying, and reduce food intake and
postprandial glucagon secretion [62].
DPP4 inhibitors delay the inactivation of incretin
hormones, also resulting in increased insulin synthesis
and decreased glucagon levels in a glucose-dependent
manner [63].
According to clinical and preclinical study results,
incretin-based therapies may have a beneﬁcial eﬀect on
hepatic steatosis and steatohepatitis, inhibit intestinal lipo-
protein production, enhance β-cell function, and produce
multiple biological actions in peripheral tissues [63, 64].
On the other hand, various nondiabetic drugs seem to
play a crucial role in insulin sensitivity and endothelial
dysfunction [65]. Several experimental evidence suggests
that overactivity of renin-angiotensin-aldosterone system
(RAAS), namely angiotensin II, interferes with insulin
resistance and glucose metabolism [66]. Thus, drugs with
RAAS blockade activity may interact with the skeletal
muscle, adipose tissue, or pancreas contributing to altered
glucose metabolism and insulin sensitivity.
It has been shown that angiotensin II interferes with
insulin metabolic signalling, induces insulin resistance, and
impairs insulin-stimulated glucose disposal. It inhibits insu-
lin receptor substrates 1 and 2 (IRS-1, IRS-2), enhances ser-
ine phosphorylation aﬀecting the PI3K (phosphoinositide
3-kinase) pathway, impairs the insulin-mediated vasodila-
tion, and also reduces the ability of IRS-1 to interact with
the activated insulin receptor [67, 68].
It has also been proposed that angiotensin II is associ-
ated with the functional impairment of pancreatic β-cells
through inﬂammation, attenuation of islet ﬁbrosis, and
oxidative damage of the pancreas. The metabolic stress,
as well as the dediﬀerentiated status of β-cells induced
by angiotensin II, has also been associated with pancreatic
β-cell failure and the potential progressive development of
T2DM [69–71].
Angiotensin II receptor blockers (ARBs) are drugs that
block the action of angiotensin II by selectively inhibiting
its binding to angiotensin II receptors on the muscles sur-
rounding blood vessels.
According to some studies, ARB medications improved
insulin sensitivity [72–74] while others showed an enhance-
ment in the early phase of insulin secretion, a signiﬁcant
eﬀect possibly attributed to the recovery of pancreatic β-cell
function [75, 76].
ACE (angiotensin-converting-enzyme) inhibitors are
also involved in the renin-angiotensin axis. It has been
proposed that ACE inhibitors promote glycemia and
glucose tolerance probably though preservation of β-cell
function [77], improvement of insulin sensitivity (via
activation of bradykinin-nitric oxide pathway) [78], anti-
inﬂammatory processes [79], and multiple other underlying
mechanisms [80, 81].
It is evident that apart from their antihypertensive
eﬀect, both ARBs and ACE inhibitors may exert beneﬁcial
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eﬀects on lipid and carbohydrate metabolism and insulin
resistance [66, 82, 83], which may explain the possible
protective role of these medications partially [84–86]. Fur-
thermore, existing evidence demonstrates a potential protec-
tive role of RAAS inhibitors in new onset of T2DM [86–88].
Fibrates are a class of hypolipidemic agents that exert
their eﬀects through activation of PPARs, namely PPARα,
which modulate carbohydrate and lipid metabolism and
adipose tissue diﬀerentiation. According to several studies,
including patients with T2DM, ﬁbrates and especially fenoﬁ-
brate improved lipidemic parameters, insulin resistance, and
glycemic control [89–91]. Moreover, a further investigation
is proposed to examine the potential protective role of
ﬁbrates in preventing T2DM [92].
Additionally, other lipid-lowering drugs such as
ANGPTL3 antisense oligonucleotides are also associated
with an improvement of insulin sensitivity [93].
Taking into account all the aforementioned, it seems
essential to clarify the underlying pathophysiologic mecha-
nisms of action for each drug, their impact on insulin resis-
tance and on the overall glucose homeostasis especially in
patients with T2DM or in patients at high risk of NOD
who also receive statin therapy [65].
4.5. Strengths and Limitations. This systematic review
includes approximately 2,000,000 participants in total
from all studies, contributing to a large cohort. In addi-
tion, a comprehensive literature search was followed, as
well as bias protection methods such as three indepen-
dent reviewers.
Of note, our data were extracted from more recent
clinical studies, the latest of which conducted in 2015, in
contrast to aforementioned review studies. Two reviews
[41, 94], with clinical trials until 2009 and 2013, respec-
tively, found no association between atorvastatin and
NOD as well as atorvastatin and deterioration of the glyce-
mic control. The review by Kostapanos et al. [94] included
a very small number of subjects and mainly low doses of
atorvastatin, while the review by Naci et al. [41] investi-
gated only the incidence of NOD in trials that were not
designed for this purpose and had no information about
the doses of atorvastatin used.
However, the limitations of the review should be
acknowledged. Firstly, the medical status of each partici-
pant (e.g., coexisting diseases) and the concomitant medi-
cations (especially the glucose-lowering agents or other
drugs with metabolic impact, as already mentioned) were
not taken into account, since data were not consistently
available. Furthermore, only clinical studies published in
PubMed were included, thus results from nonindexed tri-
als are missing. All studies not published in the English
language were excluded. Further, about a third (13 of 33)
of the included studies used observational designs. Finally,
most of the studies were not designed to investigate the
association between atorvastatin and new onset diabetes or
dysregulation of existing diabetes mellitus, but their primary
designation purpose was diﬀerent, contributing to the
heterogeneity of the results.
5. Conclusions
Our ﬁndings suggest that there is association between atorva-
statin treatment and new onset diabetes mellitus. It was also
demonstrated that atorvastatin causes worsening of glycemic
control in patients with known diabetes but only in maxi-
mum dose and not in lower doses. Nevertheless, serious
consideration needs to be placed on the cost-beneﬁt ratio
and the potential importance of these adverse eﬀects of
atorvastatin when compared to the scientiﬁcally and clini-
cally observed beneﬁcial eﬀects of statins on cardiovascular
risk. Given the wide availability of statins and relevant
databases, more studies using routine clinical data are
required to be conducted, on wider homogeneous popula-
tions of participants and with larger periods of follow-up,
in order to clarify the real association between statin ther-
apy and the development of new onset diabetes mellitus.
Moreover, the impact of other coadministrated drugs on
insulin resistance and glucose homeostasis should be taken
into deep consideration.
Hence, our review underlines the existence of a signif-
icant yet not so thoroughly investigated issue, which is
the development of NOD and also the potential deterio-
ration of the glycemic control by atorvastatin in patients
with diabetes.
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